GlassScriptPhysician profile
Catherine A White
NPI 1255677712
$1,119.72
in general payments reported to CMS, 2019-2025
17 companies · $178 in 2025
The $178 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.75 · 2022: $181 · 2023: $223 · 2024: $523 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $922.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $267.08 | 2023-2025 | Dupixent |
| Abbvie INC. | $180.32 | 2023-2025 | |
| Galderma Laboratories, L.P. | $154.19 | 2024-2025 | |
| Lilly USA, LLC | $125.00 | 2022 | |
| Abbott Laboratories | $56.18 | 2022 | |
| Glaxosmithkline, LLC. | $54.37 | 2024-2025 | Nucala |
| Genentech USA, INC. | $48.30 | 2024 | Xolair |
| Pfizer INC. | $38.44 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $30.77 | 2024 | |
| Biocryst US Sales Co., LLC | $29.28 | 2023 | Orladeyo |
| Lundbeck LLC | $27.61 | 2023 | Vyepti |
| Genzyme Corporation | $24.44 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $19.23 | 2025 | Tezspire |
| Optinose US, INC. | $18.37 | 2024 | |
| Currax Pharmaceuticals LLC | $15.75 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $15.43 | 2024 | Voquezna |
| Inspire Medical Systems, INC. | $14.96 | 2024 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.